Citi Downgrades Several Life Science Tools Vendors, Citing End Market Concerns | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citi Investment Research & Analysis today downgraded a number of life science tools firms saying end market weakness is expected to continue through 2012.

In a research report, analyst Amit Bhalla said the academic/government market will face pressure while pharma/biotech will see headwinds for the next year, limiting growth opportunities for tools vendors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?